Zyprexa, Risperdal...no se justifican frente a productos "viejos" en niños...

Lilly, J&J Antipsychotics Don't Top Old Drugs in Kids (Update2)

By Rob Waters and Tom Randall

Sept. 15 (Bloomberg) -- Best-selling antipsychotic medicines by Eli Lilly & Co. and Johnson & Johnson caused more side effects and were less effective for children with schizophrenia than a little-used 30-year-old generic drug costing one-fourth as much.

For the study, published today in the American Journal of Psychiatry, 116 children ages 8 to 19 were given molindone, an older drug available as a generic, or a newer antipsychotic, either Lilly's Zyprexa, which generated $4.8 billion in sales in 2007, or J&J's Risperdal, with $4.7 billion in revenue.

Según el estudio TEOSS, recientemente publicado, ZYPREXA y RISPERIDAL no justifican su uso frente a los antipsicóticos tradicionales mucho mas económicos.